echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Movement Disorder: Fudan Huashan Hospital, PET imaging reveals rare disease progression in frontotemporal dementia

    Movement Disorder: Fudan Huashan Hospital, PET imaging reveals rare disease progression in frontotemporal dementia

    • Last Update: 2022-01-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Frontotemporal lobar degeneration (FTLD) is a spectrum of diseases that contains a high degree of heterogeneity in terms of clinical phenotype, neuropathological features, and genetic basis
    .


    FTLD with tauopathy (FTLD-tau) accounts for 40% of all FTLD cases, and pathogenic variants in the microtubule-associated protein tau (MAPT) gene are responsible for the inherited form of FTLD-tau


    However, the relative abundance of 3R and 4R tau isoforms can be altered by pathogenic MAPT mutations, ultimately resulting in 3R, 4R or 3R+4R tauopathies
    .


    Specifically, mutations in exon 10 and surrounding introns of MAPT, which together represent an important hotspot, lead to overproduction of 4R tau


    Recent advances in tau positron emission tomography (PET) tracers have advanced our ability to identify tau deposits in the brain
    .


    Although 18F-AV-1451 tau PET has been used to image patients with at least 10 different MAPT mutations, its diagnostic performance has been inconsistent


    diagnosis

    Another traditional tau tracer, 11C-PBB3, performed well in observing 4R tau aggregation in MAPT N279K variant patients, but it is clinically limited by its inherent metabolic instability and rapid clearance
    .


    Although the utility of the second-generation tau radiotracer 18F-PI-2620 has been investigated in patients with progressive supranuclear palsy (PSP; a 4R tauopathy), its clinical value in MAPT mutation carriers remains unclear get an answer


    Hereby, Xin-Yue Zhou et al.
    from Fudan Huashan Hospital attempted to study the clinical utility of 18F-APN-1607 PET/CT in MAPT mutation carriers by analyzing 7 patient samples with different phenotypes
    .


    To this end, they thoroughly investigated the regional normalized uptake value ratio (SUVR) and patterns of tau deposition in a cross-sectional analysis



    They included 7 MAPT mutation carriers (6 within exon 10 and 1 in exon 10) and 15 healthy controls
    .


    All participants underwent 18F-APN-1607 PET/CT at baseline



    Although the 7 subjects had different clinical phenotypes, all patients exhibited marked uptake of 18 F-APN-1607, which is characterized by high-contrast signal
    .


    However, the anatomical localization of tau deposition is different in patients with different clinical symptoms


    The significance of this study is the discovery that: 18 F-APN-1607 PET/CT imaging is important for detecting tau accumulation in MAPT mutation carriers
    .


    Preliminary follow-up data also suggest the potential value of 18 F-APN-1607 PET/CT for monitoring the longitudinal trajectory of frontotemporal lobar degeneration caused by MAPT mutations
    .

    18 F-APN-1607 PET/CT imaging is important for detecting tau accumulation in MAPT mutation carriers

     

    Original source:
    Zhou X, Lu J, Liu F, et al.
    In Vivo 18 F‐APN‐1607 Tau Positron Emission Tomography Imaging in MAPT Mutations: Cross‐Sectional and Longitudinal Findings.
    Mov Disord.
    Published online November 29, 2021:mds .
    28867.
    doi:10.
    1002/mds.
    28867


    Tau Positron Emission Tomography Imaging in MAPT Mutations: Cross‐Sectional and Longitudinal Findings.
    Tau Positron Emission Tomography Imaging in MAPT Mutations: Cross‐Sectional and Longitudinal Findings.
    Leave a Comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.